The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). REMEDY Secondary Prevention of Venous Thrombo Embolism. See Table 1 and 4 legends for expansion of other abbreviations and GRADE Working Group grades of evidence. a Included patients had acute, symptomatic, objectively veri ed proximal DVT of the legs or PE. b Dabigatran 150 mg twice daily taken orally for 6 mo after an initial treatment with LMWH or IV UFH. c Warfarin adjusted to achieve an INR of 2.0-3.0 for 6 mo after an initial treatment with LMWH or IV UFH. d Active-Control study outcomes used from Schulman et al47 (REMEDY). e Allocation was concealed. Patients, providers, data collectors, and outcome adjudicators were blinded. Modi ed intention-to-treat analysis. 1.1% loss to follow-up. Not stopped early for bene t. f CI includes values suggesting no effect and values suggesting either bene t or harm. g Primary end point was composite of recurrent or fatal VTE or unexplained death. Bibliography: Schulman et al47 (REMEDY) TABLE 8 ] Summary of Findings: Dabigatran vs Placebo for Extended Treatment of VTEa,b,c Outcomes No. of Participants (Studies) Quality of the Evidence (GRADE) Relative Effect Anticipated Absolute Effects Risk with Placebo Risk Difference with Dabigatran (95% CI) All-cause mortality 1,343 Moderated because of imprecision Not estimablee Recurrent VTE 1,343 High (from 42 fewer to 55 fewer) Major bleeding 1,343 Moderated because of imprecision Not estimablef The basis for the assumed risk (eg, the median control group risk across studies) is provided in the footnotes. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 